M&A / Property
Blackbird Critical Metals Corp. Announces Conditional Approval of Fundamental Change

BBRD · Price
Executive Summary
- Blackbird Critical Metals Corp. received conditional CSE approval and shareholder consent to acquire 100% of Lir Life Sciences Inc., issuing 22,312,678 Blackbird shares to Lir shareholders.
- Prior to closing, Blackbird will consolidate its common shares on a 1.5‑for‑1 basis, reducing outstanding shares from ~7.76 M to ~5.18 M effective November 3, 2025.
- Concurrent financing includes a private placement of 3,050,270 subscription receipts at $0.35 each ($1.07 M gross) and settlement of $109,343 debt by issuing 312,408 Lir shares.
Key Details
- Acquisition Structure: Blackbird will issue 22,312,678 post‑consolidation common shares to Lir Life Sciences shareholders in exchange for all outstanding Lir shares.
- Share Consolidation: 1.5 Blackbird shares → 1 post‑consolidation share; record date October 31, 2025; effective November 3, 2025. Post‑consolidation outstanding Blackbird shares ≈ 5,175,275 (rounded).
- New Issuer Identity: After closing, the combined entity will be listed on the CSE as “Lir Life Sciences Corp.” with new CUSIP 50206C100 and ISIN CA50206C1005.
- Transaction Fee: Back Office Inc. to receive a fee equal to 2% of the transaction value, payable in 379,000 Resulting Issuer shares (four‑month hold period).
- Concurrent Financing – Private Placement:
- 3,050,270 subscription receipts @ $0.35 each → gross proceeds $1,067,594.50.
- Each receipt automatically converts to one Lir share immediately prior to closing.
- Resulting Issuer shares from this conversion subject to a voluntary four‑month hold period.
- Debt Settlement: $109,343 of outstanding debt settled by issuing 312,408 Lir shares at a deemed price of $0.35 per share; these shares will be exchanged for Resulting Issuer shares at closing.
- Trading Halt: Blackbird shares remain halted pending completion of the acquisition, consolidation, and final CSE listing approval. Anticipated post‑consolidation ticker: “SKNY”.
- Regulatory Conditions: Completion subject to CSE acceptance, shareholder approvals, and other customary conditions precedent outlined in the Purchase Agreement.
Notable Quotes
(No executive quotes were provided in the release.)